Sugi Predict

Sugi Predict / Compounds / SCHEMBL288457

SCHEMBL288457

SCHEMBL288457

NCCCCCNC(=O)CCCCC1SCC2NC(=O)NC21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.74
▸ CA12 O43570 3/20 0.62
▸ CA1 P00915 3/20 0.62
▸ CA2 P00918 3/20 0.62
▸ CA9 Q16790 3/20 0.62
▸ MEN1 O00255 1/20 0.61
▸ ABL1 P00519 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ IDE P14735 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ RIN1 Q13671 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ PLCD1 P51178 1/20 0.60
▸ ITGB1 P05556 1/20 0.57
▸ ITGA4 P13612 1/20 0.57
▸ HLCS P50747 1/20 0.57
▸ F2 P00734 1/20 0.57
▸ PRSS1 P07477 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049579 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL316398 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL10308271 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL13065003 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL9733492 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL20375017 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL10140226 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL5437180 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL20483620 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL8083249 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137943-A1 PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS THE UNIVERSITY OF CHICAGO 2023-05-04 — — US disclosed
US-20210238192-A1 VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
US-20210238192-A1 VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
US-20180071402-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES INNATE PHARMA (FR) 2018-03-15 — — US disclosed
US-9764038-B2 Enzymatic conjugation of antibodies INNATE PHARMA (FR) 2017-09-19 — — US disclosed
US-20160331842-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES ARARIS BIOTECH LTD (CH) 2016-11-17 — — US disclosed
US-9427478-B2 Enzymatic conjugation of polypeptides INNATE PHARMA (FR) 2016-08-30 — — US disclosed
US-20150165064-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES ARARIS BIOTECH LTD (CH) 2015-06-18 — — US disclosed
US-20140356385-A1 ENZYMATIC CONJUGATION OF ANTIBODIES ARARIS BIOTECH LTD (CH) 2014-12-04 — — US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 — — EP disclosed
EP-1483583-B1 ACYL FLUORIDE ACTIVATION OF CARBOXYSILYL-COATED GLASS SUBSTRATES BECKMAN COULTER INC (US) 2009-12-02 — — EP disclosed
US-20090208451-A1 HALOGEN PHOSPHONATE MONOESTERS INTEGRIGEN, INC. (US) 2009-08-20 — — US disclosed
US-20090208451-A1 HALOGEN PHOSPHONATE MONOESTERS INTEGRIGEN, INC. (US) 2009-08-20 — — US disclosed
US-7335770-B2 Triazine compounds and their analogs, compositions, and methods REDDY U5 THERAPEUTICS, INC. (US) 2008-02-26 — — US disclosed
US-7335770-B2 Triazine compounds and their analogs, compositions, and methods REDDY U5 THERAPEUTICS, INC. (US) 2008-02-26 — — US disclosed
US-20070099256-A1 Chemical derivatization, detection, and identification of peptide and protein modifications Apricot Ideas, Inc. 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071402-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES DNPEP, ENPEP, PEPD TDP1 914/4885CA12 380/4885CA1 694/4885
US-20210238192-A1 VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF VCAM1, VAPB, ICAM1 TDP1 2776/4885CA12 4722/4885CA1 4865/4885
US-20090208451-A1 HALOGEN PHOSPHONATE MONOESTERS FCGRT, PTMS, DNPEP TDP1 2212/4885CA12 42/4885CA1 59/4885
US-20140356385-A1 ENZYMATIC CONJUGATION OF ANTIBODIES DNPEP, MPO, FCGR3B TDP1 1163/4885CA12 315/4885CA1 666/4885
US-20230137943-A1 PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS PPIA, S100A4, S100A6 TDP1 1641/4885CA12 2788/4885CA1 3142/4885
US-20160331842-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES DNPEP, ENPEP, PEPD TDP1 696/4885CA12 376/4885CA1 697/4885
US-20150165064-A1 ENZYMATIC CONJUGATION OF POLYPEPTIDES DNPEP, ENPEP, PEPD TDP1 696/4885CA12 376/4885CA1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.